EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

DSCR1 deficiency ameliorates the Aβ pathology of Alzheimer’s disease by enhancing microglial activity

Chiyeol Choi, Hyerin Kim, Jiyoung Oh, Chanho Park, Min Kim, Chu-Sook Kim, Jiyoung Park iD

Life Science Alliance · 2023-02 · 6 (2) · e202201556

DOI: 10.26508/lsa.202201556 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Life Science Alliance, online erschienen am 30.11.2022. Verfasst von Chiyeol Choi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Sciences, College of Information and Bioengineering, Ulsan National Institute of Science and Technology, Ulsan, Republic of …. Hauptthemen laut MEDLINE: Alzheimer Disease, Down Syndrome. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korea Health Industry Development Institute, National Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Microglial phagocytosis and clearance are important for the removal of amyloid-β (Aβ) plaques in Alzheimer’s disease (AD). Chronic exposure of microglia to Aβ plaques leads to microglial metabolic dysfunction, and dysregulation of microglia can accelerate the deposition of Aβ plaques and cause learning and memory impairment. Thus, regulating microglial Aβ clearance is crucial for the development of therapeutics for AD-related dementia. Here, Down syndrome critical region 1 (DSCR1) deficiency ameliorated Aβ plaque deposition in the 5xFAD mouse model of AD by altering microglial activity; however, the Aβ synthesis pathway was not affected. DSCR1 deficiency improved spatial learning and memory impairment in 5xFAD mice. Furthermore, DSCR1-deficient microglia exhibited accelerated lysosomal degradation of Aβ after phagocytosis, and BV2 cells with stable knockdown of DSCR1 demonstrated enhanced lysosomal activity. RNA-sequencing analysis showed that the transcriptional signatures associated with responses to IFN-γ were significantly up-regulated in DSCR1-knockdown BV2 cells treated with Aβ. Our data strongly suggest that DSCR1 is a critical mediator of microglial degradation of amyloid plaques and a new potential microglial therapeutic target in AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseDown SyndromeAnimalsMiceMicrogliaAmyloid beta-PeptidesPlaque, AmyloidCalcium-Binding ProteinsMuscle Proteins

Substanzen

Amyloid beta-PeptidesDSCR1 protein, mouseCalcium-Binding ProteinsMuscle Proteins

Autor:innen und Institutionen

  • Department of Biological Sciences, College of Information and Bioengineering, Ulsan National Institute of Science and Technology, Ulsan, Republic of Korea.
  • Department of Biological Sciences, College of Information and Bioengineering, Ulsan National Institute of Science and Technology, Ulsan, Republic of Korea jpark@unist.ac.kr.

ORCID-Profile: Jiyoung Park

Förderung

  • Korea Health Industry Development Institute
  • National Research Foundation

Zitieren

APA

Choi, C., Kim, H., Oh, J., Park, C., Kim, M., Kim, C. S., & Park, J. (2023). DSCR1 deficiency ameliorates the Aβ pathology of Alzheimer’s disease by enhancing microglial activity. Life Science Alliance, 6(2), e202201556. https://doi.org/10.26508/lsa.202201556

Vancouver

Choi C, Kim H, Oh J, Park C, Kim M, Kim CS, et al. DSCR1 deficiency ameliorates the Aβ pathology of Alzheimer’s disease by enhancing microglial activity. Life Science Alliance. 2023;6(2):e202201556. doi:10.26508/lsa.202201556

BibTeX
@article{Choi2023,
  author = {Choi, Chiyeol and Kim, Hyerin and Oh, Jiyoung and Park, Chanho and Kim, Min and Kim, Chu-Sook and Park, Jiyoung},
  title = {DSCR1 deficiency ameliorates the Aβ pathology of Alzheimer’s disease by enhancing microglial activity},
  journal = {Life Science Alliance},
  year = {2023},
  volume = {6},
  number = {2},
  pages = {e202201556},
  doi = {10.26508/lsa.202201556}
}
Kostenlos starten →